Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

This trial is a prospective, open-label, single-center, split face randomized controlled study comparing 1.5% topical Ruxolitinib cream twice daily (BD) to aqueous cream in treating non-segmental vitiligo (NSV) of the face and neck in patient previous failed to respond to topical tacrolimus 0.1%. Aqueous cream twice daily application will be used as control group treatment. Patients with stable NSV at least 0.5% of their total body surface area (BSA) on the face and neck, as determined by the fingertip method, are screened. Recruited subjects will be asked to review their impression of change of their lesion by the end of the study using a 7-point scale.

NCT Number	NCT06719024
Lead Sponsor	Hospital Authority, Hong Kong
Conditions	Vitiligo
Enrollment	20 participants
Start Date	2024-11-29
Primary Completion	2025-06-16 (estimated)
Study Completion	2026-01-30 (estimated)
Updated on ClinicalTrials.gov	2024-12-05